Targeted Genetics' data shows tgAAC94 eases swelling in arthritic joints

By Angela McDaniels

Seattle, Oct. 31 - Targeted Genetics Corp. said it data from its phase-1 clinical trial of arthritis drug tgAAC94 demonstrated a reduction of tenderness and swelling in arthritic joints injected with a single dose of the compound.

The results were presented at the 13th Annual Congress of the European Society of Gene Therapy in Prague by Barrie J. Carter, executive vice president and chief scientific officer at Targeted Genetics.

The company said all subjects were followed for at least 12 weeks, intra-articular injections of tgAAC94 were safe and well-tolerated among patients taking conventional disease modifying anti-rheumatic drugs and no drug-related serious adverse events have been reported to date.

Targeted Genetics is a biotechnology company based in Seattle that develops targeted molecular therapies for the prevention and treatment of inflammatory arthritis and other acquired and inherited diseases with significant unmet medical need.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.